ProPhase Labs Inc (NASDAQ:PRPH) price on Wednesday, February 05, rose 8.02% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.26.
A look at the stock’s price movement, the close in the last trading session was $0.24, moving within a range at $0.22 and $0.2663. The beta value (5-Year monthly) was -0.095. Turning to its 52-week performance, $7.48 and $0.22 were the 52-week high and 52-week low respectively. Overall, PRPH moved -69.22% over the past month.
ProPhase Labs Inc’s market cap currently stands at around $7.65 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 5.88M for the company’s revenue for the quarter, with a low and high estimate of 5.88M and 5.88M respectively. The average forecast suggests up to a 35.14% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 14.8M, representing a -67.29% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PRPH is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 0 recommend PRPH as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PRPH’s current price about -48.57% and -59.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 25.35, while 7-day volatility ratio is 27.08% and 19.59% in the 30-day chart. Further, ProPhase Labs Inc (PRPH) has a beta value of -0.40, and an average true range (ATR) of 0.08. Analysts have given the company’s stock an average 52-week price target of $14, forecast between a low of $14 and high of $14. Looking at the price targets, the low is -5284.62% off current price level while to achieve the yearly target high, price needs to move -5284.62%. Nonetheless, investors will most likely welcome a -5284.62% jump to $14 which is the analysts’ median price.
If we refocus on ProPhase Labs Inc (NASDAQ:PRPH), historical trading data shows that trading volumes averaged 2.05 over the past 10 days and 608.95K over the past 3 months. The company’s latest data on shares outstanding shows there are 29.87 million shares.
The 13.96% of ProPhase Labs Inc’s shares are in the hands of company insiders while institutional holders own 6.55% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.15 million on 2024-10-31, giving us a short ratio of 7.04. The data shows that as of 2024-10-31 short interest in ProPhase Labs Inc (PRPH) stood at 97.0 of shares outstanding, with shares short falling to 0.23 million registered in 2024-09-30. Current price change has pushed the stock -66.19% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PRPH stock continues to rise going into the next quarter.
